MET and renal cell carcinoma: With the promise of current and ongoing investigations into c-Met inhibition and PD-1/PD-L1 treatment in RCC, the need for appropriate tissue sampling to facilitate effective biomarker analysis will be important for patient selection and rational clinical trial design.